Prime Medicine, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three and nine months ended September 30, 2023. Prime Medicine is a pre-revenue biotechnology company developing Prime Editing genetic therapies. It reported 18 investigational programs across four strategic indication categories and has not generated revenue from product sales.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue reported; the filing says the company has not generated revenue from product sales. | |||
| Research and development expense | $41.0 million | $25.0 million | $106.4 million | $57.7 million |
| General and administrative expense | $10.5 million | $6.6 million | $30.3 million | $20.2 million |
| Total operating expenses / operating loss | $51.5 million | $31.7 million | $136.7 million | $77.9 million |
| Net loss | $50.7 million | $29.4 million | $132.5 million | $82.5 million |
| Net loss per share, basic and diluted | $(0.55) | $(1.61) | $(1.46) | $(4.91) |
Margins and profitability: Not meaningful given the absence of product revenue. The company expects operating losses and negative operating cash flows for the foreseeable future.
Cash flow: For the first nine months of 2023, operating cash used was $121.5 million, investing cash used was $22.6 million, and financing cash provided was $0.5 million. Cash, cash equivalents, and restricted cash decreased by $143.7 million to $57.5 million, including $13.5 million of restricted cash.
Liquidity and balance sheet: At September 30, 2023, cash, cash equivalents, and investments totaled $165.3 million excluding restricted cash, or $178.8 million including restricted cash. Current assets were $184.5 million and current liabilities $39.4 million. Total assets were $239.1 million; total liabilities were $45.2 million; stockholders’ equity was $194.0 million. Accumulated deficit was $425.7 million. The filing does not report borrowings or other financial debt; liabilities include operating lease obligations.
Material changes versus prior comparable periods
- Q3 operating expenses rose $19.8 million year over year, and net loss widened $21.4 million. For the first nine months, operating expenses increased $58.9 million and net loss widened $50.0 million.
- R&D growth was driven principally by lab supplies, personnel, research activity, and facilities. G&A increased with staffing, public-company costs, professional fees, and office expansion.
- Interest income and other income increased, while fair-value changes in the Beam Therapeutics related-party investment were unfavorable in Q3 2023 compared with Q3 2022. For the nine-month comparison, the smaller Beam investment loss and higher other income partly offset increased operating costs.
- Cash, cash equivalents, and investments excluding restricted cash declined from $293.9 million at December 31, 2022 to $165.3 million at September 30, 2023. The comparison reflects operating cash use and investment activity.
Outlook, risks, contingencies, and unusual items
- Management stated that September 30 cash, cash equivalents, and investments were expected to fund operations for at least 12 months from issuance of the financial statements; elsewhere, it estimated existing resources would fund operating expenses and capital expenditures through the end of 2024. Both estimates depend on assumptions and may prove inaccurate.
- The company expects expenses to increase as it advances research and preclinical work, prepares for clinical trials, develops its platform, and expands staffing and facilities. Additional financing will be required; equity financing may dilute shareholders, while debt or collaboration arrangements may impose restrictions or require concessions.
- Prime Medicine terminated its Myeloid Therapeutics collaboration agreement effective September 7, 2023. Myeloid claims an unpaid $17.5 million milestone; Prime Medicine disputes that the milestone is due and alleges breaches by Myeloid, seeking, among other relief, $43.5 million in damages. Arbitration is ongoing; the filing does not state an outcome or a clear amount of any recognized provision.
- A Cambridge office and laboratory lease at 60 First Street is expected to commence in Q1 2024, subject to lease terms and credits. The company expects to pay up to approximately $208.7 million over its ten-year term; it was not yet recorded as a lease liability at September 30, 2023. Separately, a lease reassessment reduced recorded lease assets and liabilities by $6.1 million.
- Other key risks include scientific, preclinical, clinical, manufacturing, regulatory, intellectual-property, competition, staffing, and capital-raising uncertainties. Management noted possible exposure to inflation-related labor and R&D cost increases. It reported no material changes to previously disclosed risk factors and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress and timing of preclinical programs, IND submissions, and any clinical development; the filing provides no financial guidance on future revenue or expense amounts.
- Actual cash burn, investment balances, and whether management’s stated runway estimates remain achievable as spending grows.
- Developments and potential financial consequences of the Myeloid arbitration, including the disputed $17.5 million milestone and Prime Medicine’s counterclaims.
- Lease commencement, credits, and expected cash obligations for the 60 First Street facility.
- Future financing needs and potential dilution or other consequences of equity, debt, licensing, or collaboration arrangements.